Table 1 Subject demographic data

Number

8

9

12

17

Age at visit in years, median (range)

47.0 (40.9–54.0)

40.0 (21.5–56.5)

48.0 (39.3–66.4)

40.2 (21.5–59.9)

Gender, male/female

1/7

1/8

3/9

4/13

Ethnicity, N (%)

African-American

0 (0)

7 (77.8)

0 (0)

12 (70.6)

Caucasian

8 (100)

0 (0)

12 (100)

4 (23.5)

Hispanic

0 (0)

2 (22.2)

0 (0)

1 (11.1)

CLASI activity score, median (range)

N/A

6 (2–20)

N/A

7 (2–21)

CLASI damage score, median (range)

N/A

14 (6–20)

N/A

10 (0–20)

SLEDAI score, median (range)

N/A

0 (0–0)

N/A

0 (0–4)

Disease duration in years, median (range)^a

N/A

2.8 (0–16.3)

N/A

1.5 (0–16.3)

Lupus medications, N (%)

Topical/intralesional corticosteroids/topical immunomodulators

N/A

5 (55.6)

N/A

12 (70.6)

Hydroxychloroquine

N/A

4 (44.4)

N/A

8 (47.0)

Quinacrine

N/A

0 (0)

N/A

1 (5.9)

Methotrexate

N/A

0 (0)

N/A

1 (5.9)

None

N/A

2 (22.2)

N/A

4 (23.5)

ACR SLE criteria, N (%)^b

Discoid rash

N/A

9 (100)

N/A

17 (100)

Photosensitivity

N/A

7 (77.8)

N/A

12 (70.6)

Oral ulcers

N/A

2 (22.2)

N/A

3 (17.6)

Hematological disorder

N/A

1 (11.1)

N/A

1 (11.1)

Anti-nuclear antibody^c

N/A

3 (33.3)

N/A

3 (17.6)

Number of ACR SLE criteria, median (range)

N/A

3 (1–3)

N/A

2 (1–3)